Alexey Margolin, Ph.D., is a biotech entrepreneur, inventor, and scientist with a proven track record of founding and leading innovative companies in rare and metabolic diseases. He cofounded four biotech companies: Alnara (acquired by Eli Lilly), Alcresta (acquired by Linden Partners), Allena (IPO), and Anagram Therapeutics. His expertise spans the full spectrum of therapeutic development—from concept to commercialization—including securing public and private financing and managing programs across both orphan and prevalent diseases.

Throughout his career, Alex has played a key role in developing FDA-approved products and has been instrumental in forging strategic partnerships with advocacy groups such as the Cystic Fibrosis Foundation and the Oxalosis and Primary Hyperoxaluria Foundation. His contributions to patents and scientific literature further underscore his impact on the field. Alex has held leadership positions as CEO and Chairman at Alcresta, Allena, and Alnara and has served on multiple boards. Under his leadership, Alcresta developed RELiZORB, the first FDAapproved enzyme product for enteral feeding.

He earned his undergraduate and Ph.D. degrees from Moscow University and completed his postdoctoral training at MIT.